Iannone Robert 4

What Happened
Robert Iannone, EVP, Global Head of R&D & Chief Medical Officer at Jazz Pharmaceuticals, received a performance-based award that vested on January 16, 2026: 11,699 ordinary shares were issued to him (acquired at $0.00). To satisfy tax withholding obligations upon vesting, 4,140 of those shares were withheld and treated as a disposition at $171.16 per share, generating proceeds of $708,602. The Form 4 was filed on January 21, 2026 reporting the January 16, 2026 vesting/cashless withholding.

Key Details

• Transaction date: January 16, 2026 (vesting and tax withholding). Filing date: January 21, 2026.
• Award: 11,699 shares granted/acquired at $0.00 (performance share award).
• Withheld for taxes (disposition): 4,140 shares at $171.16 = $708,602.
• Shares owned after the transaction: not disclosed in the filing.
• Footnotes of note:
  • F1: These shares come from performance share awards granted March 3, 2023; performance goals were certified on Jan 16, 2026.
  • F2: The reporting person also acquired 71 shares under the Section 423 ESPP on Nov 28, 2025.
  • F3: The 4,140 shares were withheld from the vesting distribution to satisfy tax obligations (standard withholding).

Context
This was a performance-based vesting event (award received) with a routine tax-withholding disposition of a portion of the vested shares. The withholding is not an independent open-market sale signaling a trade decision; it is a common method to cover taxes when awards vest. The filing appears timely (filed within required business days following the Jan 16 vesting).